Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

189.25 +1.01 (+0.54%)
Streaming Delayed Price Updated: 12:28 PM EDT, Mar 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
57 58 Next >
News headline image
Biogen Stock Halted As It Faces Make-Or-Break Moment For Alzheimer's Treatment ↗
A panel of experts will debate the merits of Biogen's drug, Leqembi. 
Via Investor's Business Daily
News headline image
Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable' ↗
Senator Bernie Sanders urged the U.S. 
Via Benzinga
News headline image
Expert Ratings for Biogen ↗
 
Via Benzinga
News headline image
FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval ↗
FDA Peripheral and Central Drugs Advisory Committee is meeting Friday (June 9) to discuss a supplemental marketing application for Leqembi (lecanemab) submitted by Eisai Co Ltd (OTC: ESALY) for... 
Via Benzinga
News headline image
Biogen Rises As 'Relatively Benign' FDA Documents Suggest An Alzheimer's Approval Is Near ↗
The FDA's advisors will consider the full approval of Leqembi on Friday. 
Via Investor's Business Daily
News headline image
Thinking Of Buying Boston Properties? Here Are The Properties And Tenants You'd Add To Your Portfolio ↗
When investors consider the purchase of a real estate investment trust (REIT), along with performance and dividends, they need to consider the properties and tenants that accompany that REIT. Several... 
Via Benzinga
News headline image
$100 Invested In Biogen 15 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Biogen Unusual Options Activity For May 26 ↗
 
Via Benzinga
News headline image
Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure ↗
 
Via Benzinga
News headline image
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
News headline image
Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump ↗
The news also benefits Biogen's partner Eisai and rival Eli Lilly. 
Via Investor's Business Daily
News headline image
How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run ↗
Shares surged into and out of the company's R&D Day, which included a surprise. 
Via Investor's Business Daily
News headline image
Analyst Ratings for Biogen ↗
 
Via Benzinga
News headline image
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $5,500 Today ↗
 
Via Benzinga
News headline image
(BIIB) - Analyzing Biogen's Short Interest ↗
 
Via Benzinga
News headline image
P/E Ratio Insights for Biogen ↗
 
Via Benzinga
News headline image
Elliott Wave Technical Analysis: Biogen Inc. - Monday, May 8 ↗
Looking for longs on the way up into wave (3), as long as every downside pullback is a three wave move. 
Via Talk Markets
News headline image
Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption? ↗
A steady rotation out of biotech and healthcare stocks into the Nasdaq-100 large-cap tech stocks can be unnerving for portfolio managers. 
Via Talk Markets
News headline image
3 Biotech Stocks That Are Revolutionizing Healthcare in 2023 ↗
Here are three of the best biotech stocks to buy; each is on the verge of significant breakthroughs that may send the price higher. 
Via InvestorPlace
News headline image
1 Major Advantage Biogen May Have Over Pharma Giant Eli Lilly in a Multibillion-Dollar Market ↗
Analysts are bullish on Biogen's Alzheimer's drug, Leqembi, projecting it may generate over $10 billion in sales at its peak. 
Via The Motley Fool
News headline image
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside. 
Via MarketBeat
News headline image
Biogen Unusual Options Activity ↗
 
Via Benzinga
News headline image
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
News headline image
Eli Lilly's Alzheimer's Drug Is Just Version 1.0. But It's Still On Track For Blockbuster Status, Analyst Says. ↗
An analyst says Lilly's donanemab could become a blockbuster in its second year on the market. 
Via Investor's Business Daily
News headline image
These 2 Pharma Stocks Might Face Off Soon -- but They Could Both Win ↗
There's no rule that says a market must have only one winner. 
Via The Motley Fool
News headline image
3 Reasons to Buy Biogen Stock (and 1 to Sell) ↗
The stock has been rallying but how it performs from here will likely depend on the fate of its Alzheimer's treatment, Leqembi. 
Via The Motley Fool
News headline image
Here’s What Eli Lilly’s Latest Clinical Win Means For Investors ↗
The biotech's prospects continue to get brighter. 
Via The Motley Fool
News headline image
Here's Why Eli Lilly's Alzheimer's Drug Could Be the Real Deal ↗
Eli Lilly stock may look expensive, but there's still plenty of value here for long-term investors. 
Via The Motley Fool
News headline image
Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance ↗
 
Via Benzinga
News headline image
Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen ↗
Wednesday, Eli Lilly And Co (NYSE: LLY) announced positive results of the TRAILBLAZER-ALZ 2 Phase 3 study of  
Via Benzinga
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.